Phase 2 Study Evaluating the Safety and Efficacy of Microneedle-mediated Delivery of Doxorubicin (D-MNA) in Patients With Nodular Basal Cell Carcinoma.

NCT06608238 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Nodular Basal Cell Carcinoma

Interventions

DRUG: D-MNA 200µg
DRUG: D-MNA 100µg
OTHER: Microneedle Array Alone

Sponsor

SkinJect, Inc.